Mandel-Brehm Josh 4

What Happened Josh Mandel-Brehm, a director of ProMIS Neurosciences, received two derivative awards on May 20, 2026 totaling 16,500 shares (5,500 and 11,000). Each award is reported at $0.00 per share (no cash paid on grant) and recorded as an "A" (grant/award) on the Form 4. These were awards of derivative securities (e.g., stock options or RSUs) rather than open-market purchases or sales.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (filed timely).
• Awards: 5,500 shares and 11,000 shares, total 16,500 shares; reported price $0.00 per share.
• Footnotes / vesting:
  • F1: One award vests in full on May 20, 2027, subject to continued Board service.
  • F2: The other award: 25% vested at grant; remaining 75% vests ratably over 36 months, subject to continued Board service.
• Shares beneficially owned after the transaction are not specified in the provided data.
• Transaction type: derivative grant (A). No sale, purchase in the open market, or exercise reported.

Context These grants are typical director compensation aimed at retention and aligning interests with shareholders; they do not represent an immediate cash purchase or sale. Because they are derivative awards with vesting conditions, they may convert into common shares only if vesting conditions are met. Awards like these are informative about compensation and retention but should not be read as a direct bullish or bearish trade by the insider.